glp 1 agonist clinical trials 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀 ⁣ ⁣ Randomized, placebo-controlled of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong Cardiovascular outcomes in major trials

10.1080/00325481.2021.2002616 78 WolfeD.KanjiS.YazdiF.BarbeauP.RiceD.BeckA.et al (2020)

Manufacturers are therefore maintaining dual formulation strategies to capture both segments while extending product life cycles through delivery innovation

Semaglutides sales reached $21.2 billion in 2023 with an 88% increase, becoming top 3 best-selling drugs worldwide

UK GLP-1 Receptor Agonist Market Trends The UK is experiencing a rise in type 2 diabetes and obesity cases, which is increasing the use and demand for GLP-1 receptor agonists

[DOI] [PubMed] [Google Scholar] 110.Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Bonaca M.P

These cardiovascular advantages have made GLP-1 medications a preferred choice for type 2 diabetes patients with established cardiovascular disease